Advanced Therapies Manufacturing Strategy Digital 

Assess the current manufacturing landscape in the context of the COVID-19 pandemic. What are the short and long term implications for advanced therapeutics development?

July 14 - 15, 2020 | Virtual Event

Advanced Therapies Manufacturing Strategy Digital | Challenges of Manufacturing Biologics Through CMO

Advanced Therapies Manufacturing Strategy Digital | Challenges of Manufacturing Biologics Through CMO

The outsourcing biologics industry is expected to grow to $87.5 billion by 2027.

With the approval of the first recombinant DNA product, Humulin, biologics has brought great enthusiasm and excitement to doctors, patients and others in the pharma field. Utilizing human life tissues, the practice of biologics can ultimately pave the way for personalized treatments to specific cures based on your DNA and live tissues. With so much promise, small pharma companies are outsourcing R&D to CMOs, but this process continues to show some bumps in the road. For example, how do pharma companies go from clinical to commercial working in partnership with CMOs? How do they increase speed to market? 

To continue reading, please fill out the download form.........

To have the handbook sent to your inbox, email nuria.frances@unitelifesciences.com. 


Please note: That all fields marked with an asterisk (*) are required.